Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology
Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology
复制标题
DOI：
10.1148/rg.2020200021
复制
发表时间：
2020-10-01
期刊：
影响因子：
5.5
通讯作者：
Buchpiguel, Carlos A.
中科院分区：
文献类型：
--
作者：
Gomes Marin, Jose Flavio;Nunes, Rafael F.;Buchpiguel, Carlos A.
治疗诊断学是指诊断生物标志物与在患病细胞或组织中共享特定靶点的治疗剂的配对。核医学，特别是在肿瘤学中的应用，目前是临床和研究场景中治疗诊断概念的最重要组成部分之一。核医学中的治疗诊断学，或称核治疗诊断学，是指使用放射性化合物通过表达特定的疾病靶点（如细胞表面受体或膜转运蛋白）来成像生物现象，然后使用专门设计的试剂将电离辐射传递到表达这些靶点的组织。核治疗诊断方法引起了越来越多的兴趣，并获得了与分子成像和个性化医疗的增长平行的重要性，有助于为各种疾病提供定制的管理;改善患者选择，预测反应和毒性，并确定预后;避免徒劳和昂贵的诊断检查和治疗许多疾病。作者概述了核医学中的治疗诊断方法，首先回顾了核治疗诊断学的主要概念和独特特征，并回顾性讨论了自早期应用以来治疗诊断剂的进展，并强调了成像特征。先进的概念，氟18-氟脱氧葡萄糖PET治疗诊断学的作用，以及治疗诊断学的发展和未来的方向进行了讨论。(C)RSNA，2020年
Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to applications in oncology, is currently one of the greatest components of the theranostic concept in clinical and research scenarios. Theranostics in nuclear medicine, or nuclear theranostics, refers to the use of radioactive compounds to image biologic phenomena by means of expression of specific disease targets such as cell surface receptors or membrane transporters, and then to use specifically designed agents to deliver ionizing radiation to the tissues that express these targets. The nuclear theranostic approach has sparked increasing interest and gained importance in parallel to the growth in molecular imaging and personalized medicine, helping to provide customized management for various diseases; improving patient selection, prediction of response and toxicity, and determination of prognosis; and avoiding futile and costly diagnostic examinations and treatment of many diseases. The authors provide an overview of theranostic approaches in nuclear medicine, starting with a review of the main concepts and unique features of nuclear theranostics and aided by a retrospective discussion of the progress of theranostic agents since early applications, with illustrative cases emphasizing the imaging features. Advanced concepts regarding the role of fluorine 18-fluorodeoxyglucose PET in theranostics, as well as developments in and future directions of theranostics, are discussed. (C) RSNA, 2020